Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).

Autor:	Miki M; Department of Breast Surgery, Kobe University Hospital, Kobe, Japan; mikimayu@med.kobe-u.ac.jp.; Department of Breast Surgery, Hyogo Cancer Center, Hyogo, Japan., Takao S; Department of Breast Surgery, Hyogo Cancer Center, Hyogo, Japan., Konishi M; Department of Breast Surgery, Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan., Shigeoka Y; Department of Oncology, Yodogawa Christian Hospital, Osaka, Japan., Miyashita M; Department of Breast Surgery, Konan Hospital, Hyogo, Japan., Suwa H; Department of Breast Surgery, Hyogo Prefectural Amagasaki Medical Center, Hyogo, Japan., Miyoshi Y; Department of Breast Surgery, Hyogo College of Medicine, Hyogo, Japan., Hirokaga K; Department of Breast Surgery, Hyogo Cancer Center, Hyogo, Japan., Okuno T; Department of Breast Surgery, Kobe City Nishi-kobe Medical Center, Kobe, Japan., Yamagami K; Department of Breast Surgery, Shinko Hospital, Kobe, Japan., Imamura M; Department of Breast Surgery, Hyogo College of Medicine, Hyogo, Japan., Murase K; Department of Breast Surgery, Hyogo College of Medicine, Hyogo, Japan., Yanai A; Department of Breast Surgery, Hyogo College of Medicine, Hyogo, Japan., Tanino H; Department of Breast Surgery, Kobe University Hospital, Kobe, Japan.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2021 Jun; Vol. 41 (6), pp. 3121-3126.
DOI:	10.21873/anticanres.15096
Abstrakt:	Background/aim: S-1, a 5-fluorouracil(5-FU) oral anti-cancer drug, has been traditionally used with a schedule of 4-week oral administration followed by 2-week rest for breast cancer treatment. We, herein, aimed to investigate the clinical efficacy and safety of a schedule of 2-week oral administration followed by 1-week rest for patients with metastatic breast cancer. Patients and Methods: We enrolled patients with HER2-negative metastatic breast cancer who had not received prior chemotherapy. S-1 was administered consecutively for 2-weeks followed by a 1-week rest. Results: Between September 1, 2013 and August 31, 2016, 32 patients were enrolled. The median follow-up time was 32.1 months. The median progression-free survival (PFS) was 9.4 months. Overall survival (OS) was 41.0 months, time to treatment failure (TTF) was 7.8 months, response rate (RR) was 31.3%, and disease control rate (DCR) was 78.1%. The incidence of grade 3 side-effects was not high. Conclusion: The 3-week schedule of S-1 can be considered useful as a treatment for patients with metastatic breast cancer, helping in maintaining a high quality of life. (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu